Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$30.74 - $49.16 $6.15 Million - $9.83 Million
-200,000 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$31.4 - $69.84 $6.28 Million - $14 Million
200,000 New
200,000 $6.59 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.29B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Great Point Partners LLC Portfolio

Follow Great Point Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Great Point Partners LLC with notifications on news.